Market PotentialThe market for wet AMD drugs is projected to exceed $9B in the U.S./EU by 2030.
Product DifferentiationDURAVYU is differentiated from the current standard of care treatments because it incorporates vorolanib, a tyrosine kinase inhibitor, administered via an implant that releases the drug steadily over the course of around nine months.
Regulatory PathwayEyePoint held an end-of-Phase-2 meeting with the FDA in late April, where it got confirmation from the FDA on its proposed Phase 3 trial design for Duravyu in wet AMD.